$PHVS News

Pharvaris N.V. (PHVS) Presents at The 2026 Eastern Allergy Conference - Slideshow

Pharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Citizens Maintains Market Outperform on Pharvaris, Lowers Price Target to $74

Pharvaris Q1 EPS $(0.69) Beats $(0.77) Estimate

Pharvaris Prices Underwritten Offering Of 3,874,664 Shares At $29.68 Per Share

Pharvaris Presents Data Evaluating Safety Margins Of Administration Of Deucrictibant IR Capsule In Combination With Deucrictibant XR Tablet At CIIC Spring 2026 Conference

Pharvaris N.V. (PHVS) Presents at CIIC Spring 2026 Conference - Slideshow

Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors.

Wolfe Research Initiates Coverage On Pharvaris with Outperform Rating, Announces Price Target of $42

Wedbush Maintains Outperform on Pharvaris, Raises Price Target to $42

Did Phase 3 Completion and 2025 Losses Just Shift Pharvaris’ (PHVS) Investment Narrative?

Pharvaris' Deucrictibant Could Be a Game Changer Pending Phase III Results, RBC Says

Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder

RBC Capital Maintains Outperform on Pharvaris, Lowers Price Target to $51

Pharvaris NV (NASDAQ:PHVS) Reports Q4 2025 Financial Results and Key Pipeline Milestones

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Pharvaris shares are trading lower after the company reported worse-than-expected Q4 EPS results.

Pharvaris shares are trading lower after the company reported worse-than-expected Q4 EPS results.

Pharvaris Q4 EPS $(0.84) Misses $(0.69) Estimate

Does Pharvaris (PHVS) Have the Potential to Rally 59.93% as Wall Street Analysts Expect?